Mesenchymal stem cell therapy in acute kidney injury (AKI): review and perspectives

CONCLUSIONS: Cellular therapy with MSCs is very promising and should be part of the treatment of AKI patients in combination with other approaches already available, helping to accelerate recovery and/or slow the progression to chronic kidney disease. Randomized, multicentre controlled studies are needed to develop robust protocols that validate population-based cell therapy with MSCs.
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research